VC says that Theranos' founder is 'quintessential Silicon Valley.' Compliment or insult?

Pressure continues to mount on embattled diagnostics company Theranos and its famous billionaire founder Elizabeth Holmes following a WSJ exposé that cast doubt on the accuracy of its tests and (little-used) Edison technology to detect diseases with just a few drops of blood. "I asked Theranos why my blood test results were wildly off from my 'traditional' labs, but no one ever replied" is the self-explanatory title of a piece in Quartz by Jean-Louis Gassée, a venture partner at Silicon Valley's Allegis Capital. The WSJ's findings hit insiders like Gassée hard because, as he writes, "Holmes' story is quintessential Silicon Valley. A Stanford drop-out who learned Mandarin and then sold C++ compilers to Chinese universities, Holmes holds more than a dozen patents, is financed by prominent venture investors, and has ascended to the financial pinnacle (Theranos, still private, is said to be worth $9 billion, of which Holmes would own about $4.5 billion)." The passage begs the (unanswered) question: is the development of an overhyped (but still potentially useful) technology part of that narrative too? More | Here's previous FMD coverage of the development | More

Suggested Articles

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.

In one of the longest studies to date in high-risk heart disease, researchers found no significant difference in death rates over more than 10 years.